Underperforming sites are a persistent industry challenge, directly impacting trial timelines and budgets: 37% of sites enroll poorly, and 11% never enroll a single patient.¹ SYNETIC’s foundation of over 500,000 unique institutions and 3 million study sites across 62 countries equips PSI’s sponsors and operational teams with real-time, data-driven insights into site capabilities, operational efficiency, and patient recruitment performance, ensuring that even the most complex global trials stay on track and meet aggressive timelines.

SYNETIC is a new addition to PSI’s award-winning INTELIA Clinical Trial Intelligence Platform, which unites operational excellence, predictive analytics, and AI-enabled decision support to optimize every phase of trial planning and execution.

What SYNETIC delivers for the industry and PSI sponsors:

• Instant Site Intelligence: Rapid generation of comprehensive site lists with in-depth data on institutional capabilities, workload, and prior performance
• AI-Driven Site Scoring: Automated algorithmic ranking of sites by protocol fit based on enrollment history, therapeutic expertise, and geographic performance
• Agentic AI and Semantic Search: More accurate study matching using sophisticated agentic AI, leveraging Natural Language Processing (NLP) to query SYNETIC’s data set using semantic search and LLM-augmented reasoning
• Data-driven Site Matching: Enhanced feasibility assessments powered by advanced AI models for targeted outreach to sites most likely to successfully recruit
• Interactive Knowledge Graphs: Predictive analytics based on complex relationships across millions of data points, connecting institutions, investigators, and trial performance
• Real-Time Insights: Evidence-based insights in real time through a next-gen semantic data architecture powered by PSI’s enterprise ontology

“INTELIA enables pharma and biotech sponsors to see what works and what doesn’t for their trial before it begins,” said Kirill Soldatov, Head of Process Improvement at PSI. “SYNETIC takes this to the next level, by eliminating blind spots in site selection and patient enrollment. It’s not just a platform – it’s a core enabler of PSI’s promise to sponsors: that teams will deliver, on time, every time, even under the most demanding conditions and in any geography.”

Reference
¹ Tufts CSDD, 2024: “Clinical Site Enrollment Performance Trends.”